Stock Events

CalciMedica 

$3.96
5
-$0.18-4.36% Thursday 20:00

Statistics

Day High
4.12
Day Low
3.9
52W High
8.38
52W Low
1.75
Volume
4,109
Avg. Volume
37,367
Mkt Cap
44.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

7
NOV
Earnings
 

Earnings

7NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-23.43
-15.62
-7.8
0.01
Expected EPS
-0.5625
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALC. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals is involved in the development of small molecule drugs for serious diseases, including inflammatory conditions, which puts it in direct competition with CalciMedica's focus on treatments for acute pancreatitis and other inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, but its expansion into other therapeutic areas, including inflammatory and respiratory diseases, makes it a competitor.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie operates in areas including immunology and chronic inflammatory conditions, directly competing with CalciMedica's development of treatments for diseases with inflammatory components.
AMGEN
AMGN
Mkt Cap179.38B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, making it a competitor in the biopharmaceutical space targeting similar conditions as CalciMedica.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, with a significant focus on inflammatory diseases, positioning it as a competitor to CalciMedica.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, but its interest in expanding into other areas, including inflammatory diseases, makes it a potential competitor.
Novartis
NVS
Mkt Cap244.75B
Novartis is a global healthcare company that operates across various segments, including pharmaceuticals that target inflammatory diseases, making it a competitor in the same therapeutic area as CalciMedica.
Pfizer
PFE
Mkt Cap164.39B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including inflammation and immunology, directly competing with CalciMedica's focus areas.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a broad range of health conditions, including inflammatory diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca operates in several key therapeutic areas, including respiratory, inflammation, and autoimmunity, positioning it as a competitor to CalciMedica in the inflammation segment.

Analyst Ratings

20$Average Price Target
The highest estimate is $20.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Show more...
CEO
Employees
13
Country
US
ISIN
US38942Q2021

Listings

XNAS
US
CALC